Science & discoveries / Case series · 15 patients
CAR-T and autoimmune diseases: hope from a small case series
What follow-up of 15 patients showed, and what remains open.
Key takeaway
Striking results in a few patients begin a research journey rather than establish a universal conclusion.
What was studied
The study included eight patients with lupus, three with inflammatory myositis and four with systemic sclerosis. They received CD19-directed CAR-T cells after preparatory chemotherapy. Median follow-up was 15 months.
What was found
The authors reported remission according to study criteria in lupus, a major response in myositis and lower disease activity in systemic sclerosis. Patients stopped immunosuppression within this supervised process.
What it does not prove
There was no control group. Cytokine release syndrome, one case of mild neurotoxicity and one hospital admission for pneumonia were reported. The small sample cannot fully assess rare risks or long-term relapses.
Why it matters
The finding asks whether reorganising part of the immune system can provide lasting benefit. It is not a reason to stop existing treatment. Funding included the German Research Foundation and other sources.
Sources
- CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up ↗NEJM · Müller and colleagues · Accessed 5 September 2026
An editorial explanation referring to the listed sources. General information; individual interpretation and treatment require clinical assessment.
Updated 5 September 2026. How we prepare our content